Correction: Autologous P63+ lung progenitor cell transplantation in idiopathic pulmonary fibrosis: a phase 1 clinical trial
Main text
Zhang S, Zhou M, Shao C, Zhao Y, Liu M, Ni L, Bao Z, Zhang Q, Zhang T, Luo Q, Qu J, Xu Z, Zuo W. 2025. Autologous P63+ lung progenitor cell transplantation in idiopathic pulmonary fibrosis: a phase 1 clinical trial. eLife 13:RP102451. doi: 10.7554/eLife.102451.
Published 4 March 2025
[Details of correction]
The Results section and Table 2 have been corrected. The original manuscript contained two minor inaccuracies that arose during the final consolidation of clinical records. In the Results section (“Safety analysis of REGEND001”), the description of fever-related adverse events has been corrected from “1 grade II” to “2 grade II”. In Table 2 (Adverse events), the value for “Hemoptysis” at 1 M was incorrectly reported as 2 (16.67) and has been corrected to 1 (8.33). These corrections are limited to specific data points and do not affect the overall results, statistical analyses, or conclusions of the study.
[Results: Safety analysis of REGEND001]
[Corrected text:]
Fever is one of the mostly common cell therapy-related AEs (21.4%, 2 grade II, 2 grade I)
[Original text:]
Fever is one of the mostly common cell therapy-related AEs (21.4%, 1 grade II, 2 grade I)
[Table 2:]
[The corrected Table 2 is shown here:]
Table 2. Adverse events*
| No. (%) of Patients With Adverse Events | ||||
|---|---|---|---|---|
| Events | 0.6 M | 1 M | 2 M | 3.3 M |
| Any adverse event | 2 (16.67) | 3 (25.00) | 3 (25.00) | 3 (25.00) |
| Serious adverse events | 2 (16.67) | 0 | 1 (8.33) | 1 (8.33) |
| Fatal adverse events | 0 | 0 | 0 | 0 |
| Adverse events leading to discontinuation | 0 | 0 | 0 | 0 |
| Frequent adverse events:† | ||||
| Likely related to Bronchoscopy | ||||
| Hemoptysis | 1 (8.33) | 1 (8.33) | 1 (8.33) | 1 (8.33) |
| Fever | 0 | 1 (8.33) | 2 (16.67) | 1 (8.33) |
| White blood cell counts increased | 0 | 1 (8.33) | 0 | 1 (8.33) |
| Productive cough | 1 (8.33) | 1 (8.33) | 0 | 0 |
| Bronchitis | 1 (8.33) | 0 | 0 | 0 |
| Others | ||||
| COVID-19 | 0 | 0 | 3 (25.00) | 3 (25.00) |
| Bronchitis | 2 (16.67) | 0 | 0 | 1 (8.33) |
| Hypokalemia | 1 (8.33) | 0 | 1 (8.33) | 0 |
*Shown are adverse events occurred in patients from baseline examination to the end of the study visit. Events are listed in descending order of frequency.
†The frequent adverse events were defined as those with an incidence ≥2 patients, which were ordered by frequency of occurrence here.
[The originally published Table 2 is also shown for reference:]
Table 2. Adverse events*
| No. (%) of Patients With Adverse Events | ||||
|---|---|---|---|---|
| Events | 0.6 M | 1 M | 2 M | 3.3 M |
| Any adverse event | 2 (16.67) | 3 (25.00) | 3 (25.00) | 3 (25.00) |
| Serious adverse events | 2 (16.67) | 0 | 1 (8.33) | 1 (8.33) |
| Fatal adverse events | 0 | 0 | 0 | 0 |
| Adverse events leading to discontinuation | 0 | 0 | 0 | 0 |
| Frequent adverse events:† | ||||
| Likely related to Bronchoscopy | ||||
| Hemoptysis | 1 (8.33) | 2 (16.67) | 1 (8.33) | 1 (8.33) |
| Fever | 0 | 1 (8.33) | 2 (16.67) | 1 (8.33) |
| White blood cell counts increased | 0 | 1 (8.33) | 0 | 1 (8.33) |
| Productive cough | 1 (8.33) | 1 (8.33) | 0 | 0 |
| Bronchitis | 1 (8.33) | 0 | 0 | 0 |
| Others | ||||
| COVID-19 | 0 | 0 | 3 (25.00) | 3 (25.00) |
| Bronchitis | 2 (16.67) | 0 | 0 | 1 (8.33) |
| Hypokalemia | 1 (8.33) | 0 | 1 (8.33) | 0 |
*Shown are adverse events occurred in patients from baseline examination to the end of the study visit. Events are listed in descending order of frequency.
†The frequent adverse events were defined as those with an incidence ≥ 2 patients, which were ordered by frequency of occurrence here.
The article has been corrected accordingly.
Article and author information
Author details
Version history
Copyright
© 2026, Zhang et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 3
- views
-
- 0
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.